Skip to content
Article Rich – Lifestyle
Author:
Inhibikase Therapeutics
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
July 23, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
July 14, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
May 20, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026